These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

429 related items for PubMed ID: 16364054

  • 1. In vitro comparison of clodronate, pamidronate and zoledronic acid effects on rat osteoclasts and human stem cell-derived osteoblasts.
    Kellinsalmi M, Mönkkönen H, Mönkkönen J, Leskelä HV, Parikka V, Hämäläinen M, Lehenkari P.
    Basic Clin Pharmacol Toxicol; 2005 Dec; 97(6):382-91. PubMed ID: 16364054
    [Abstract] [Full Text] [Related]

  • 2. Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298.
    Coxon FP, Helfrich MH, Van't Hof R, Sebti S, Ralston SH, Hamilton A, Rogers MJ.
    J Bone Miner Res; 2000 Aug; 15(8):1467-76. PubMed ID: 10934645
    [Abstract] [Full Text] [Related]

  • 3. Aminobisphosphonates cause osteoblast apoptosis and inhibit bone nodule formation in vitro.
    Idris AI, Rojas J, Greig IR, Van't Hof RJ, Ralston SH.
    Calcif Tissue Int; 2008 Mar; 82(3):191-201. PubMed ID: 18259679
    [Abstract] [Full Text] [Related]

  • 4. Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts.
    Reinholz GG, Getz B, Pederson L, Sanders ES, Subramaniam M, Ingle JN, Spelsberg TC.
    Cancer Res; 2000 Nov 01; 60(21):6001-7. PubMed ID: 11085520
    [Abstract] [Full Text] [Related]

  • 5. Osteoclasts but not osteoblasts are affected by a calcified surface treated with zoledronic acid in vitro.
    Schindeler A, Little DG.
    Biochem Biophys Res Commun; 2005 Dec 16; 338(2):710-6. PubMed ID: 16243296
    [Abstract] [Full Text] [Related]

  • 6. Breast cancer cells inhibit spontaneous and bisphosphonate-induced osteoclast apoptosis.
    Hussein O, Tiedemann K, Komarova SV.
    Bone; 2011 Feb 16; 48(2):202-11. PubMed ID: 20849994
    [Abstract] [Full Text] [Related]

  • 7. Antitumor effects of bisphosphonates.
    Green JR.
    Cancer; 2003 Feb 01; 97(3 Suppl):840-7. PubMed ID: 12548584
    [Abstract] [Full Text] [Related]

  • 8. Inhibition of osteoblast function in vitro by aminobisphosphonates.
    Orriss IR, Key ML, Colston KW, Arnett TR.
    J Cell Biochem; 2009 Jan 01; 106(1):109-18. PubMed ID: 19003973
    [Abstract] [Full Text] [Related]

  • 9. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo.
    Hughes DE, Wright KR, Uy HL, Sasaki A, Yoneda T, Roodman GD, Mundy GR, Boyce BF.
    J Bone Miner Res; 1995 Oct 01; 10(10):1478-87. PubMed ID: 8686503
    [Abstract] [Full Text] [Related]

  • 10. Dissociation of the pro-apoptotic effects of bisphosphonates on osteoclasts from their anti-apoptotic effects on osteoblasts/osteocytes with novel analogs.
    Plotkin LI, Manolagas SC, Bellido T.
    Bone; 2006 Sep 01; 39(3):443-52. PubMed ID: 16627025
    [Abstract] [Full Text] [Related]

  • 11. The activity of zoledronic Acid on neuroblastoma bone metastasis involves inhibition of osteoclasts and tumor cell survival and proliferation.
    Peng H, Sohara Y, Moats RA, Nelson MD, Groshen SG, Ye W, Reynolds CP, DeClerck YA.
    Cancer Res; 2007 Oct 01; 67(19):9346-55. PubMed ID: 17909043
    [Abstract] [Full Text] [Related]

  • 12. Cytostatic and apoptotic effects of bisphosphonates on prostate cancer cells.
    Dumon JC, Journé F, Kheddoumi N, Lagneaux L, Body JJ.
    Eur Urol; 2004 Apr 01; 45(4):521-8; discussion 528-9. PubMed ID: 15041119
    [Abstract] [Full Text] [Related]

  • 13. Effect of risedronate on osteoblast differentiation, expression of receptor activator of NF-κB ligand and apoptosis in mesenchymal stem cells.
    Fujita H, Kurokawa K, Ogino T, Ono M, Yamamoto M, Oka T, Nakanishi T, Kobayashi N, Tanaka N, Ogawa T, Suzaki E, Utsumi K, Sasaki J.
    Basic Clin Pharmacol Toxicol; 2011 Aug 01; 109(2):78-84. PubMed ID: 21332944
    [Abstract] [Full Text] [Related]

  • 14. Indirect antitumor effects of bisphosphonates on prostatic LNCaP cells co-cultured with bone cells.
    Tanaka T, Kawashima H, Ohnishi K, Matsumura K, Yoshimura R, Matsuyama M, Kuratsukuri K, Nakatani T.
    Anticancer Res; 2009 Apr 01; 29(4):1089-94. PubMed ID: 19414350
    [Abstract] [Full Text] [Related]

  • 15. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates.
    Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino FH, Rogers MJ.
    J Pharmacol Exp Ther; 2001 Feb 01; 296(2):235-42. PubMed ID: 11160603
    [Abstract] [Full Text] [Related]

  • 16. Bisphosphonates: mode of action and pharmacology.
    Russell RG.
    Pediatrics; 2007 Mar 01; 119 Suppl 2():S150-62. PubMed ID: 17332236
    [Abstract] [Full Text] [Related]

  • 17. Exposing human epithelial cells to zoledronic acid can mediate osteonecrosis of jaw: an in vitro model.
    Saracino S, Canuto RA, Maggiora M, Oraldi M, Scoletta M, Ciuffreda L, Vandone AM, Carossa S, Mozzati M, Muzio G.
    J Oral Pathol Med; 2012 Nov 01; 41(10):788-92. PubMed ID: 22650360
    [Abstract] [Full Text] [Related]

  • 18. Bisphosphonates for the prevention of bone metastases.
    Coleman RE.
    Semin Oncol; 2002 Dec 01; 29(6 Suppl 21):43-9. PubMed ID: 12584694
    [Abstract] [Full Text] [Related]

  • 19. Pulse treatment with zoledronic acid causes sustained commitment of bone marrow derived mesenchymal stem cells for osteogenic differentiation.
    Ebert R, Zeck S, Krug R, Meissner-Weigl J, Schneider D, Seefried L, Eulert J, Jakob F.
    Bone; 2009 May 01; 44(5):858-64. PubMed ID: 19442618
    [Abstract] [Full Text] [Related]

  • 20. Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells.
    Coxon FP, Thompson K, Roelofs AJ, Ebetino FH, Rogers MJ.
    Bone; 2008 May 01; 42(5):848-60. PubMed ID: 18325866
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.